Sibylla is a preclinical-stage company focused on developing new small molecule degraders with a novel mechanism of action for unmet medical needs. Its PPI-FIT platform, powered by computer simulations and AI/ML methods, enables the discovery and development of compounds that induce the degradation of a target protein by interfering with its folding pathway. By leveraging this innovative approach, Sibylla advances the identification and development of small molecules that act on targets involved in various types of diseases.